Orrick advised Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, on its follow-on offering of 3,820,000 shares of common stock. The offering generated net proceeds of approximately $80 million and closed on December 13, 2019. J.P. Morgan, Cowen and Evercore ISI acted as the joint-bookrunning managers, and LifeSci Capital LLC acted as co-manager.
The Orrick team advising Rocket was led by capital markets partner Andrew Thorpe and included associates Melissa Frayer
and Will Peifer